Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 22;113(12):1645-50.
doi: 10.1038/bjc.2015.409. Epub 2015 Dec 3.

Risk prediction tools for cancer in primary care

Affiliations
Review

Risk prediction tools for cancer in primary care

Juliet Usher-Smith et al. Br J Cancer. .

Abstract

Numerous risk tools are now available, which predict either current or future risk of a cancer diagnosis. In theory, these tools have the potential to improve patient outcomes through enhancing the consistency and quality of clinical decision-making, facilitating equitable and cost-effective distribution of finite resources such as screening tests or preventive interventions, and encouraging behaviour change. These potential uses have been recognised by the National Cancer Institute as an 'area of extraordinary opportunity' and an increasing number of risk prediction models continue to be developed. The data on predictive utility (discrimination and calibration) of these models suggest that some have potential for clinical application; however, the focus on implementation and impact is much more recent and there remains considerable uncertainty about their clinical utility and how to implement them in order to maximise benefits and minimise harms such as over-medicalisation, anxiety and false reassurance. If the potential benefits of risk prediction models are to be realised in clinical practice, further validation of the underlying risk models and research to assess the acceptability, clinical impact and economic implications of incorporating them in practice are needed.

PubMed Disclaimer

Conflict of interest statement

WH has had many research grants relating to cancer diagnostics from non-commercial sources and has been involved in developing a number of cancer risk prediction tools for use in primary care. He was the clinical lead for the revision of the NICE 2005 guidance (NG12) on the topic of selection of patients for cancer investigation. His contribution to this article is in a personal capacity and should not to be interpreted as representing the view of the Guideline Development Group or NICE. He has received travel support to give lectures and attend conferences, plus occasional speaker's fees, from conference organisers in the charitable and educational sector, although none from commercial sources. SJG developed and evaluated the Cambridge diabetes risk score, which is freely available. He has evaluated the predictive utility of diabetes and cardiovascular disease risk scores. JE has received travel support to give lectures and attend conferences, plus occasional speaker's fees, from conference organisers in the charitable and educational sector, although none from commercial sources. He received consultancy fees from AP Benson Ltd from 2000–2004 relating to the GRAIDS and Cyrillic software. JUS and FMW have no competing interests to declare.

References

    1. Brindle P, Beswick A, Fahey T, Ebrahim S (2006) Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92: 1752–1759. - PMC - PubMed
    1. Chiang PP-C, Glance D, Walker J, Walter FM, Emery JD (2015) Implementing a QCancer risk tool into general practice consultations: an exploratory study using simulated consultations with Australian general practitioners. Br J Cancer 112: S77–S83. - PMC - PubMed
    1. Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N, Hall P, Pharoah P, Burton H (2013) Incorporating genomics into breast and prostate cancer screening: assessing the implications. Genet Med 15: 423–432. - PMC - PubMed
    1. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48: 232–242. - PMC - PubMed
    1. Colditz G A, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, Hunter DJ (2000) Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 11: 477–488. - PubMed

LinkOut - more resources